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Abstract
Background: Cardiovascular disease risk increases when lipoprotein metabolism is dysfunctional. We have developed a
computational model able to derive indicators of lipoprotein production, lipolysis, and uptake processes from a single
lipoprotein profile measurement. This is the first study to investigate whether lipoprotein metabolism indicators can
improve cardiovascular risk prediction and therapy management.
Methods and Results: We calculated lipoprotein metabolism indicators for 1981 subjects (145 cases, 1836 controls) from
the Framingham Heart Study offspring cohort in which NMR lipoprotein profiles were measured. We applied a statistical
learning algorithm using a support vector machine to select conventional risk factors and lipoprotein metabolism indicators
that contributed to predicting risk for general cardiovascular disease. Risk prediction was quantified by the change in the
Area-Under-the-ROC-Curve (DAUC) and by risk reclassification (Net Reclassification Improvement (NRI) and Integrated
Discrimination Improvement (IDI)). Two VLDL lipoprotein metabolism indicators (VLDLE and VLDLH) improved cardiovascular
risk prediction. We added these indicators to a multivariate model with the best performing conventional risk markers. Our
method significantly improved both CVD prediction and risk reclassification.
Conclusions: Two calculated VLDL metabolism indicators significantly improved cardiovascular risk prediction. These
indicators may help to reduce prescription of unnecessary cholesterol-lowering medication, reducing costs and possible
side-effects. For clinical application, further validation is required.
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Introduction
The Framingham Risk score predicts cardiovascular risk based
on six variables: age, diabetes, smoking status, treated and
untreated systolic blood pressure, total cholesterol, and HDL
(High Density Lipoprotein) cholesterol [1]. Newer lipoprotein
measurement methods have attempted to improve risk prediction
by quantifying lipoprotein subclasses by size [2–7] or density [8]
range. However, the lipoprotein size information is little used in
clinical practise so far, because its relation to cardiovascular risk is
unclear. However, the lipoprotein size information contains
implicit information about lipoprotein metabolism, which causes
the size distribution. This metabolic information may be relevant
for the prediction of cardiovascular disease.
We have developed a computational model to analyze
measured lipoprotein subclass profiles in terms of the underlying
metabolic activity [9–12]. Briefly, lipoproteins transport lipids,
mainly triglycerides and cholesterol, through the bloodstream. The
model includes Apolipoprotein B (ApoB)-containing lipoprotein
particles ranging from large Very Low Density Lipoprotein
(VLDL) through the smaller Intermediate Density Lipoprotein
(IDL) and Low Density Lipoprotein (LDL) particles. Lipoprotein
particles are produced by the liver, they lose fat to different tissues
and become smaller in the lipolysis process, and they are finally
taken up by the liver again. The main proteins responsible for the
lipolysis process are Hepatic Lipase (HL) in the liver and
Lipoprotein Lipase (LPL) in other tissues. The model can calculate
ratios of lipoprotein production, lipolysis, and uptake processes
from a single lipoprotein profile measurement; we call these ratios
‘lipoprotein metabolism indicators’.
ApoB-containing lipoproteins are proatherogenic because an
accumulation of especially small dense LDL particles may lead to
plaque formation in veins and arteries. Growing plaques may over
time lead to CVD. Small dense LDL particles can form when the
liver does not clear LDL particles from the bloodstream effectively.
This is a metabolic disorder of the liver, that will also have an
effect on VLDL, the metabolic precursor of LDL, because when
overloaded the liver will also take up less VLDL, and perhaps
produce more VLDL to lose excess fat. Therefore, we hypothe-
sized that adding metabolic information in the form of lipoprotein
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metabolism indicators to conventional risk factors can improve
cardiovascular risk prediction. We evaluated this hypothesis for
subjects from the Framingham offspring cohort.
Methods
Study Sample and Risk Factors
In this study we used measured information from subjects
studied in the 4th examination of the Framingham Heart Study
Offspring cohort, as recorded in the database of Genotypes and
Phenotypes (dbGaP) [13]. Subjects were included when they had
no history of cardiovascular disease, gave written informed consent
for general research use, had complete NMR lipoprotein profiles
recorded, and had a complete record of conventional cardiovas-
cular risk factors. Cardiovascular events were carefully recorded
during the follow-up period for all subjects.
Computational Modeling
We applied the Particle Profiler computational model [9,10] to
NMR lipoprotein profiles [14]. Profiles were based on the original
NMR measurements, to which Liposcience’s LP3 algorithm was
applied. Slight modifications to the previously published Particle
Profiler [12] fitting procedure can be found in Text S1 (Methods).
We calculated ratios of all modeled processes (lipoprotein
production, total lipoprotein lipolysis, HL lipolysis, LPL lipolysis,
liver lipoprotein attachment, liver lipoprotein uptake) in each of
three sets of lipoprotein size ranges (VLDL through LDL, VLDL
only, IDL through LDL). The calculated ratios of modelled
processes are lipoprotein metabolism indicators that serve as
candidate diagnostics.
Outcomes
Subjects who experienced a general cardiovascular event, as
defined by the Framingham Heart Study [14], within 10 years
after the NMR measurements, were designated as ‘cases’, all
others as ‘controls’. The Framingham definition includes coronary
death, myocardial infarction, coronary insufficiency, angina,
ischemic stroke, hemorrhagic stroke, transient ischemic attack,
peripheral artery disease, and heart failure.
Statistical Analysis
We used a statistical learning algorithm (a nonlinear L2-norm
support vector machine [15,16]) to correlate predictor variables
with the Cardiovascular Disease (CVD) outcome. This analysis
was carried out in order to identify the most predictive ‘lipoprotein
metabolic indicator’ diagnostics, and evaluate their performance.
We grouped the predictor variables into three datasets: 1.
conventional cardiovascular risk parameters, without cholesterol
(see Table 1); 2. conventional cholesterol parameters (see Table 1)
and 3. lipoprotein metabolism indicators (see Text S1 (Methods)). A
detailed explanation of the procedure we used for constructing the
multivariate model is provided in Text S1 (Methods). In summary,
in order to obtain a model similar to the Framingham Risk Score,
we selected the six most predictive variables from dataset 1, the
two most predictive markers from dataset 2, and further markers
from dataset 3. In the first phase, using dataset 1, we included ‘age’
and ‘gender’ in the model. We then added in succession those
variables that contributed most to improving predictive perfor-
mance of the model, measured as the area under the Receiver
Operating Characteristic (ROC) curve (or C-statistic) [17]. The
area under the ROC curve is the conventional statistic used for
Table 1. Markers present in raw datasets 1 and 2, the third
dataset contains lipoprotein metabolic ratios, defined in Text
S1 (Methods).
Classical risk variables (dataset 1)
Age
Sex
Systolic blood pressure physician 1
Diastolic blood pressure physician 1
Systolic blood pressure physician 2
Diastolic blood pressure physician 2
Systolic blood pressure nurse
Diastolic blood pressure nurse
Cigarettes per day
Inhales
Smokes sigars
Smokes pipe
Spouse smokes
BMI
Blood pressure medication
Glucose
Cholesterol markers (dataset 2)
Total cholesterol
HDL cholesterol
VLDL cholesterol (NMR)
LDL cholesterol (NMR)
HDL cholesterol (NMR)
doi:10.1371/journal.pone.0092840.t001
Table 2. Baseline characteristics of the subjects.*
Characteristic
Men
(N=946)
Women
(N=1035)
Mean age – yr 49.269.3 49.569.0
Cholesterol – mg/dl
Total 204636 205640
HDL 44611 56615
Blood pressure – mm Hg
Systolic (nurse) 127616 122619
Diastolic (nurse) 80610 75610
Blood pressure medication – no. (%) 126 (13.3) 128 (12.4)
Body-mass index 27.663.8 25.865.1
Smoking
Smokes and inhales 201 (21.2) 219 (21.2)
Cigarettes per day 5.2612.1 4.269.6
Smokes cigars – no. (%) 46 (4.9) 2 (0.2)
Smokes pipe – no. (%) 28 (3.0) 0 (0)
Spouse smokes – no. (%) 344 (36.4) 450 (43.5)
Glucose – mg/dl 95618 91622
* Plus-minus values are means 6 SD. To convert the values for cholesterol to
millimoles per liter, multiply by 0.02568. The body-mass index is the weight in
kilograms divided by the square of the height in meters. HDL denotes
high-density lipoprotein.
doi:10.1371/journal.pone.0092840.t002
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comparing the predictive performance of diagnostics. A procedure
that successively adds the best predicting variables is frequently
referred to as ‘‘forward variable selection’’ (see e.g. [18]). Having
selected the biomarkers from dataset 1, we proceeded in a similar
manner with datasets 2 and 3, consecutively adding the most
predictive variables to the model. We added markers from dataset
3 that gave a substantial improvement in ROC prediction and that
were not correlated with markers already in the model (r2,0.25);
this procedure led to inclusion of two additional markers from
dataset 3. For comparison, we also included a dataset with the
selected markers from dataset 1, plus total and HDL cholesterol.
We used a separate training and test-set for marker selection, but
evaluated the final result using the complete dataset. All
multivariate analyses were performed using Numerical Python.
The results of the multivariate analyses are various predictive
models including different diagnostic markers. The CVD risk
predictions of these models then need to be compared using
suitable statistics. We compared the area under the ROC curve of
the various models (DAUC) using the method by de Long and a
binomial exact test, calculated in MedCalc, version 11.5.1.0. Also,
we used Platt’s algorithm to transform the predictions computed
by SVM into class probabilities for computing reclassification
statistics [19,20]. Reclassification was quantified using the ‘Net
Reclassification Improvement’ (NRI) using 6% and 20% risk
cutoffs for the ‘medium’ and ‘high’ risk classes and the ‘Integrated
Discrimination Improvement’ (IDI, a risk cutoff-independent
method) as suggested by Pencina [21]. The first ROC analysis is
the classical comparison of diagnostic power. The reclassification
comparison is more sensitive and gives more clinically relevant
information, because it measures how people are redistributed
over risk categories using the new diagnostics, and evaluates
whether that change was correct.
Results
Baseline Characteristics
Of the 2142 selected subjects 145 cases and 1836 controls were
found to have a complete record of all relevant parameters and
thus were included in the analysis. Baseline characteristics of the
subjects are shown in Table 2. The mean age was 4969 years,
52% was female.
Multivariate Models
The variables included in the final multivariate models are
shown in Table 3. The first selected lipoprotein metabolism
indicators was ln
kVLDLlpl
Jin,VLDL
 !
, which we call the ‘VLDL Extrahe-
patic lipolysis indicator’ or VLDLE. This indicator is a ratio
between the VLDL lipolysis rate related to lipoprotein lipase
(kVLDLlpl ) and the influx of particles due to production in the liver
and lipolysis of larger particles (Jin,VLDL). The second selected
lipoprotein metabolism indicator ln
kVLDLhl
Jprod,VLDL
z
kVLDLa,liver
Jprod,VLDL
2
0
BBB@
1
CCCA,
which we call the ‘VLDL Hepatic turnover indicator’ or VLDLH,
Table 3. Variables included in final multivariate models.
Conventional markers
without cholesterol Conventional markers LDLc LDLc + HDLc LDLc + HDLc + VLDLE + VLDLH
Age Age Age Age Age
Sex Sex Sex Sex Sex
Cigarettes per day Cigarettes per day Cigarettes per day Cigarettes per day Cigarettes per day
Blood pressure medication Blood pressure medication Blood pressure medication Blood pressure medication Blood pressure medication
Systolic blood pressure
(nurse)
Systolic blood pressure
(nurse)
Systolic blood pressure
(nurse)
Systolic blood pressure
(nurse)
Systolic blood pressure (nurse)
Glucose Glucose Glucose Glucose Glucose
Total Cholesterol LDL cholesterol LDL cholesterol LDL cholesterol
HDL cholesterol HDL cholesterol HDL cholesterol
VLDL Extrahepatic lipolysis indicator
VLDL Hepatic turnover indicator
doi:10.1371/journal.pone.0092840.t003
Table 4. Areas under the ROC curve for the cross-validated multivariate models and their improvement versus a random predictor.
Model AUC SE
AUC improvement
from random
% incremental AUC improvement
from random
Conventional, no cholesterol 0.759 0.0204 0.259 0.0
Conventional 0.795 0.0193 0.295 12.2
LDLc 0.791 0.0192 0.291 11.0
LDLc + HDLc 0.797 0.0192 0.297 12.8
LDLc + HDLc + VLDLE + VLDLH 0.812 0.0192 0.312 17.0
doi:10.1371/journal.pone.0092840.t004
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is the average of two ratios: that between the rate constant of
hepatic VLDL lipolysis (kVLDLhl ) and the VLDL particle production
flux (Jprod,VLDL), and that between the rate of VLDL attachment
to the liver (kVLDLa,liver ) and the VLDL particle production flux.
Further explanation of the mathematical notation of these
indicators can be found in Text S1 (Methods).
ROC analysis of Multivariate Models
Tables 4 and 5 show the results of a Receiver-Operating-
Characteristic (ROC) analysis for general cardiovascular disease.
Table 4 displays the area under the curve, its improvement over a
predictor drawn at random, and a percentage incremental
improvement of the last statistic. Results of the statistical analyses
comparing the curves are shown in Table 5. Our method
significantly improved CVD prediction over accepted risk
markers, as measured by the Area-Under-the-ROC-Curve
(DAUC). The improvement of our model versus a model with
classical Framingham risk markers, including total cholesterol and
HDLc, was DAUC=0.0177 with p= 0.0055. The improvement of
our model versus a model including LDLc and HDLc was
DAUC=0.0150 with p= 0.0067. In comparison, the model
including LDLc and HDLc did not significantly improve risk
prediction over the model including total cholesterol and HDLc,
with DAUC=0.00268, and p= 0.6003. As expected, adding total
and HDL cholesterol to other classical Framingham risk factors
did significantly improve risk prediction, with DAUC=0.0354 and
p= 0.0003. The statistical test thus showed that adding lipoprotein
metabolism indicators to a model that includes existing cardio-
vascular risk factors significantly improved the area under the
ROC curve for this population, with respect to conventional risk
markers.
Reclassification analysis
Table 6 shows the results of the reclassification analysis. Risk
reclassification, using low, middle, and high risk classes, and also
using the category independent methods was significantly
improved when including LDLc, HDLc, and VLDL metabolism
indicators. The improvement of the model including VLDL
metabolism indicators versus the model including classical
Framingham risk markers was quantified as NRI= 0.090, with
p= 0.014; for the category independent method IDI= 0.051, with
p,0.0001. The improvement of the model including VLDL
metabolism indicators versus the model including LDLc and
HDLc was quantified as NRI= 0.0828, with p= 0.013; for the
category independent method IDI= 0.040, p = 0.0004. In com-
parison, the model including total cholesterol and HDLc versus
that including LDLc and HDLc was nonsignificant, with
NRI= 0.008 and IDI= 0.011. Adding total and HDL cholesterol
to non-cholesterol Framingham risk factors did give a significant
improvement, with NRI= 0.111 and p= 0.009; for the category
independent method IDI= 0.040, p,0.0001. Lipoprotein metab-
olism indicators therefore add reclassification power to the NMR
lipoprotein profile.
In addition, we calculated NRI reclassification statistics for
subjects classified as at ‘Intermediate risk’ when using Framing-
ham risk markers (Table 7). These subjects would be eligible for
drug treatment in primary prevention. The analysis shows how
many subjects not experiencing events would not need treatment,
and how many experiencing events would be put on more
intensive treatment when using the new diagnostics. The NRI was
0.15 (p = 0.0481) when comparing these conventional markers to
LDLc and HDLc, and 0.37 (p,0.0001) when comparing them to
the model including lipoprotein metabolism indicators. When
looking at reclassified events separately (n = 48), the two
mentioned methods improved classification by 6% and 13%
respectively, but both improvements were non-significant. Impor-
tantly, there was a 9% reclassification improvement of non-events
(n = 422) when including LDLc and HDLc, and a 25%
reclassification improvement of non-events using lipoprotein
metabolism indicators, both with p,0.0001. The study therefore
shows that 25% of subjects that conventional Framingham risk
factors would needlessly include in the ‘intermediate risk’ category,
were reclassified to ‘low risk’ using lipoprotein metabolism
indicators.
Discussion
This is the first study in which ‘lipoprotein metabolism
indicators’ have been used for cardiovascular disease risk
prediction. These diagnostics are ratios of lipoprotein production,
lipolysis, and uptake processes derived from a single lipoprotein
profile measurement using computational modelling. We demon-
strate that incorporation of two lipoprotein metabolism indicators
significantly improves CVD risk prediction as measured by the
area-under-the-ROC-curve. Reclassification is also significantly
improved over conventional risk markers. The most important
predictor, the ‘VLDL Extrahepatic lipolysis indicator’ or
VLDLE,is a ratio between the VLDL lipolysis rate related to
lipoprotein lipase (LPL) and the influx of particles due to
production in the liver and lipolysis of larger particles. As LPL
mainly acts extrahepatically, this ratio gives information about the
capacity of extrahepatic tissue to absorb triglycerides from VLDL
particles in the fasting state. The second indicator, we call the
‘VLDL Hepatic turnover indicator’ or VLDLH, is the average of
two ratios: that between hepatic VLDL lipolysis and VLDL
production, and that between VLDL attachment to the liver and
Table 5. Statistical analysis of areas under the ROC curve for the cross-validated multivariate models.
Model 1 Model 2 Difference AUC ROC curve Standard Error P value
Conventional no cholesterol Conventional 0.0354 0.00979 0.0003
Conventional no cholesterol LDLc 0.0323 0.00991 0.0011
Conventional LDLc + HDLc 0.00268 0.00512 0.6003
Conventional LDLc + HDLc + VLDLE + VLDLH 0.0177 0.00637 0.0055
LDLc LDLc + HDLc 0.00580 0.00566 0.3055
LDLc LDLc + HDLc + VLDLE + VLDLH 0.0208 0.00735 0.0047
LDLc + HDLc LDLc + HDLc + VLDLE + VLDLH 0.0150 0.00552 0.0067
doi:10.1371/journal.pone.0092840.t005
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VLDL production. This combined ratio relates to the capacity of
the liver to process VLDL particles, both through lipolysis and
particle attachment to the liver. Inspection of the risk model (see
Text S1, Results) shows that LDLc remains the most important
lipoprotein-related predictor of CVD events. HDLc is an
important risk modifier, especially when no blood pressure
medication is used. When using blood pressure medication,
VLDLE becomes important; the lower this indicator, the slower
incoming VLDL particles are lipolysed extrahepatically, the higher
the risk. VLDLH is most important for determining the border
between low and medium risk, especially for men and when not
using blood pressure medication; the lower VLDLH, the less
hepatic VLDL turnover per produced particle, the higher the risk.
These interpretations show that the new risk prediction can be
understood in relation to lipoprotein pathophysiology and genetic
variation (in LPL and other genes pertinent to VLDL processes).
Examining the reclassification of subjects that were classified as
at ‘intermediate risk’ by Framingham risk factors is of special
clinical significance. The intermediate risk group consists of those
individuals that should be treated according to international
guidelines [21]. Subjects that are reclassified move to either the
high risk (more intensive treatment) or low risk (no treatment)
groups. Our results show that a net 25% of subjects in this group
that will not get cardiovascular disease after 10 years are moved to
the low risk group. The reclassification of people with events to the
high risk group was not significant, probably due to the low
number of cases in this group (n= 48). In other words, there is a
group of people that are classified as at ’intermediate risk’ using the
Framingham risk factors, but of whom we know with hindsight
that they do not suffer from a cardiovascular event. When
performing a diagnosis using VLDLE and VLDLH, 25% of this
subject group is reclassified to the low risk category, and these
subjects would therefore not have to take the medication the
guidelines prescribe for the intermediate risk category needlessly.
Extrapolating these results to clinical practice directly is not
straightforward, most importantly because treatment decisions are
most often made based on one or two parameters (such as LDLc
and HDLc) and not based on a complete set of risk markers.
However, because our multivariate model for the classical
Framingham markers is already an improvement over the two-
variable approach used in practice, a 25% improvement using our
final risk model will most likely be an underestimate for a
comparison with a two-variable approach used in the same
population. Future studies will need to point out whether the 25%
improvement can be validated in other populations, and whether a
population with more CVD cases will also yield significant
reclassification improvement for cases in the Intermediate risk
category. Our methodology can be readily applied to any past
studies in which NMR lipoprotein profiles have been measured.
Possible subjects of further investigation includes determining risk
in younger or older persons, differences in ethnic groups, and the
benefits for secondary prevention. The Particle Profiler model can
also derive lipoprotein metabolism indicators from other methods
for measuring lipoprotein profiles [2–7]. Other future investigation
can compare the results of modelling the data from these methods.
The current study has one technical limitation that deserves
mention: the NMR spectra were recorded with an older version of
the technology that is currently available. This limitation does not
affect the method to derive lipoprotein metabolism indicators.
Because of newer NMR methodology, the accuracy of lipoprotein
metabolism indicators will increase in future studies.
In summary, in a sample of 1981 subjects from the Framingham
offspring cohort, we found 2 lipoprotein metabolism indicators
that together significantly improved general cardiovascular risk
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prediction, as quantified by the area under the ROC curve and by
reclassification statistics. These indicators may help to reduce the
number of people that unnecessarily take cholesterol-lowering
medication, reducing costs and possible side-effects. Clinical
application will require further validation of these findings.
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